Capstone Investment Advisors
VRTX icon

Capstone Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Capstone Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Buy
23,900
+14,400
+152% +$6.71M 0.02% 271
2025
Q4 		$4.31M Sell
9,500
-10,500
-53% -$4.53M 0.01% 397
2025
Q3 		$7.83M Buy
20,000
+1,600
+9% +$669K 0.01% 362
2025
Q2 		$8.19M Sell
18,400
-2,300
-11% -$1.06M 0.02% 294
2025
Q1 		$10M Sell
20,700
-18,500
-47% -$8.62M 0.03% 301
2024
Q4 		$15.8M Buy
39,200
+7,700
+24% +$3.57M 0.04% 260
2024
Q3 		$14.7M Buy
31,500
+5,400
+21% +$2.59M 0.04% 233
2024
Q2 		$12.2M Buy
26,100
+8,100
+45% +$3.52M 0.04% 271
2024
Q1 		$7.52M Sell
18,000
-31,900
-64% -$13.5M 0.03% 327
2023
Q4 		$20.3M Buy
49,900
+7,700
+18% +$2.84M 0.06% 204
2023
Q3 		$14.7M Buy
42,200
+5,700
+16% +$1.99M 0.07% 211
2023
Q2 		$12.8M Buy
36,500
+4,900
+16% +$1.65M 0.06% 216
2023
Q1 		$9.96M Sell
31,600
-55,800
-64% -$16.7M 0.05% 244
2022
Q4 		$25.2M Buy
87,400
+15,300
+21% +$4.66M 0.18% 76
2022
Q3 		$20.9M Sell
72,100
-1,900
-3% -$547K 0.13% 98
2022
Q2 		$20.9M Sell
74,000
-21,000
-22% -$5.62M 0.1% 120
2022
Q1 		$24.8M Sell
95,000
-145,100
-60% -$34.4M 0.07% 215
2021
Q4 		$52.7M Sell
240,100
-17,800
-7% -$3.46M 0.09% 190
2021
Q3 		$46.8M Buy
257,900
+81,200
+46% +$15.9M 0.09% 194
2021
Q2 		$35.6M Buy
176,700
+40,600
+30% +$8.49M 0.08% 216
2021
Q1 		$29.2M Sell
136,100
-13,300
-9% -$2.92M 0.09% 212
2020
Q4 		$35.3M Sell
149,400
-9,400
-6% -$2.16M 0.12% 137
2020
Q3 		$43.2M Buy
158,800
+14,800
+10% +$4.08M 0.22% 83
2020
Q2 		$41.8M Buy
144,000
+82,400
+134% +$22.3M 0.28% 62
2020
Q1 		$14.7M Sell
61,600
-42,500
-41% -$9.75M 0.24% 75
2019
Q4 		$22.8M Buy
104,100
+34,400
+49% +$6.96M 0.12% 177
2019
Q3 		$11.8M Buy
69,700
+8,100
+13% +$1.43M 0.08% 248
2019
Q2 		$11.3M Buy
61,600
+5,900
+11% +$1.03M 0.08% 264
2019
Q1 		$10.2M Buy
55,700
+27,200
+95% +$5.02M 0.09% 207
2018
Q4 		$4.72M Buy
28,500
+9,200
+48% +$1.59M 0.06% 256
2018
Q3 		$3.72M Buy
+19,300
New +$3.44M 0.04% 308
2014
Q3 		– Sell
-7,700
Closed -$729K – 508
2014
Q2 		$729K Buy
+7,700
New +$540K 0.01% 335
2013
Q3 		– Sell
-13,600
Closed -$1.09M – 564
2013
Q2 		$1.09M Buy
+13,600
New +$1M 0.01% 343

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capstone Investment Advisors's VRTX Position: Q1 2026 in Review

Capstone Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, buying an estimated $306K and bringing the position to 3,895 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #684.

Capstone Investment Advisors first reported a position in VRTX in Q1 2016 and has held it in 25 quarters since. The position peaked at $18.4M in Q3 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Capstone Investment Advisors held 3,895 shares of Vertex Pharmaceuticals worth $1.74M as of Q1 2026.
  • Capstone Investment Advisors bought 656 Vertex Pharmaceuticals shares in Q1 2026, an estimated $306K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #684 holding.
  • Capstone Investment Advisors first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
  • Capstone Investment Advisors's Vertex Pharmaceuticals position peaked at $18.4M in Q3 2021.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.